Mitochondrial encephalomyopathy (ME) is a group of multisystem disorders caused by mitochondrial dysfunction. The clinical manifestations of ME are diverse, complex and the prevalence of the disease is low. However, ME patients generally first visit the mental health department for their complicated psychiatric symptoms. This paper introduced the clinical information, diagnosis and treatment of a case who suffered from mitochondrial encephalomyopathy presenting with lactic acidosis and stroke-like episode （MELAS） with psychiatric complications, and further reviewed the literatures on the clinical features and the diagnostic methods of the disease to raise the clinicians′ awareness and to avoid any misdiagnosis and mistreatment.

Mitochondrial encephalomyopathy (ME) is a group of multisystem disorders caused by mitochondrial dysfunction. The clinical manifestations of ME are diverse, complex and the prevalence of the disease is low. However, ME patients generally first visit the mental health department for their complicated psychiatric symptoms. This paper introduced the clinical information, diagnosis and treatment of a case who suffered from mitochondrial encephalomyopathy presenting with lactic acidosis and stroke-like episode （MELAS） with psychiatric complications, and further reviewed the literatures on the clinical features and the diagnostic methods of the disease to raise the clinicians′ awareness and to avoid any misdiagnosis and mistreatment.

Objective:To observe the clinical efficacy of tuina with intensive stimulation at tender points plus medication in treating cervical intervertebral disc herniation (CIDH).
Methods:Totally 158 CIDH patients were randomized into an observation group and a control group by their visit sequence, 79 cases in each group. The control group was intervened by oral administration of Meloxicam tablets, 7.5 mg for each dose, once each day. The observation group was additionally intervened by tuina with intensive stimulation at tender points based on the treatment given to the control group, once each day. The therapeutic efficacy was evaluated after successive 14-day treatment for the two groups.
Results:The total effective rate was 92.4% in the observation group, significantly higher than 81.0% in the control group (P<0.05). The visual analogue scale (VAS) scores dropped significantly after the treatment in both groups (bothP<0.01), and the VAS score of the observation group was significantly lower than that of the control group (P<0.01).
Conclusion:Tuina with intensive stimulation at tender points plus oral administration of Meloxicam tablets can produce a more significant efficacy in treating CIDH than taking Meloxicam alone, thus worth promoting in clinic.